K
Ki-Young Jung
Researcher at Seoul National University Hospital
Publications - 245
Citations - 4872
Ki-Young Jung is an academic researcher from Seoul National University Hospital. The author has contributed to research in topics: Epilepsy & Medicine. The author has an hindex of 30, co-authored 217 publications receiving 3536 citations. Previous affiliations of Ki-Young Jung include New Generation University College & Korea University.
Papers
More filters
Journal ArticleDOI
Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study
Ronald B. Postuma,Alex Iranzo,Michele T.M. Hu,Birgit Högl,Bradley F. Boeve,Raffaele Manni,Wolfgang H. Oertel,Isabelle Arnulf,Luigi Ferini-Strambi,Monica Puligheddu,Elena Antelmi,Valérie Cochen De Cock,Dario Arnaldi,Brit Mollenhauer,Aleksandar Videnovic,Karel Sonka,Ki-Young Jung,Dieter Kunz,Yves Dauvilliers,Federica Provini,Simon J.G. Lewis,Jitka Bušková,Milena Pavlova,Anna Heidbreder,Jacques Montplaisir,Joan Santamaria,Thomas R Barber,Ambra Stefani,Erik K. St. Louis,Michele Terzaghi,Annette Janzen,Smandra Leu-Semenescu,G. Plazzi,Flavio Nobili,Friederike Sixel-Doering,Petr Dusek,Frederik Bes,Pietro Cortelli,Kaylena A. Ehgoetz Martens,Jean-François Gagnon,Carles Gaig,Marco Zucconi,Claudia Trenkwalder,Ziv Gan-Or,Christine Lo,Michal Rolinski,Philip Mahlknecht,Evi Holzknecht,Angel R Boeve,Luke N. Teigen,Gianpaolo Toscano,Geert Mayer,Silvia Morbelli,Benjamin Dawson,Amélie Pelletier +54 more
TL;DR: In a prospective multicentre study involving 1280 patients with idiopathic RBD, Postuma et al. test the predictive power of 21 prodromal markers of neurodegeneration, providing a template for planning neuroprotective trials.
Journal ArticleDOI
Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study
Woo Jin Lee,Woo Jin Lee,Soon-Tae Lee,Soon-Tae Lee,Jangsup Moon,Jangsup Moon,Jun Sang Sunwoo,Jun Sang Sunwoo,Jung Ick Byun,Jung Ick Byun,Jung Ah Lim,Jung Ah Lim,Tae Joon Kim,Tae Joon Kim,Yong Won Shin,Yong Won Shin,Keon-Joo Lee,Keon-Joo Lee,Jin-Sun Jun,Jin-Sun Jun,Han Sang Lee,Han Sang Lee,Soyun Kim,Kyung Il Park,Keun Hwa Jung,Keun Hwa Jung,Ki-Young Jung,Ki-Young Jung,Manho Kim,Manho Kim,Sang Kun Lee,Sang Kun Lee,Kon Chu,Kon Chu +33 more
TL;DR: Tocilizumab might be a good treatment strategy for treating AE refractory to conventional immunotherapies and rituximab, and manifests as early at 1 month after treatment initiation.
Journal ArticleDOI
Treatment strategies for autoimmune encephalitis
TL;DR: In this review, the agents used for first- and second-line immunotherapy are discussed and recent attempts at finding new treatment options are introduced.
Journal ArticleDOI
Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort
Woo Jin Lee,Soon-Tae Lee,Jung Ick Byun,Jun Sang Sunwoo,Tae Joon Kim,Jung Ah Lim,Jangsup Moon,Han Sang Lee,Yong Won Shin,Keon-Joo Lee,Soyun Kim,Keun Hwa Jung,Ki-Young Jung,Kon Chu,Sang Kun Lee +14 more
TL;DR: This study provides Class IV evidence that rituximab improves mRS scores for patients with autoimmune limbic encephalitis who fail first-line therapy, regardless of autoantibody status.
Journal ArticleDOI
Altered Expression of the Long Noncoding RNA NEAT1 in Huntington's Disease.
Jun Sang Sunwoo,Soon-Tae Lee,Soon-Tae Lee,Wooseok Im,Wooseok Im,Mijung Lee,Mijung Lee,Jung Ick Byun,Jung Ick Byun,Jung Ick Byun,Kunhwa Jung,Kunhwa Jung,Kyung Il Park,Ki-Young Jung,Ki-Young Jung,Sang Kun Lee,Sang Kun Lee,Kon Chu,Kon Chu,Manho Kim,Manho Kim +20 more
TL;DR: The notion that NEAT1 upregulation in HD contributes to the neuroprotective mechanism against neuronal injury rather than the pathological process underlying neurodegeneration in HD is supported.